Heart failure & cardiomyopathies
Tafamidis Medication Adherence and Persistence in Patients with Transthyretin Amyloid Cardiomyopathy in Japan
Authors' conclusion
This study found high adherence rates to tafamidis in this real-world Japanese patient population.
Study context
- Population
- Adults with ATTR-CM treated with tafamidis, Japanese Medical Data Vision (MDV) claims database, March 2019–August 2021
- Participants
- 210 adults
- Outcome
- Adherence (mMPR, adherent if ≥80%; PDC)
- Follow-up
- Average 14 month
Methodological detailsnon-interventional, claims database
- Non-interventional
- Claims database
Main finding
As reported in the abstract
Adherence (mMPR)
Mean modified medication possession ratio (mMPR)
96%
Median mMPR (IQR 97-101%)
100%
Adherent (mMPR ≥80%)
93%
Observational data: associations, not effects.
Further findings
Proportion of days covered (PDC) · average 14 month follow-up
- Mean PDC
- 93.6%
- Median PDC (IQR 93-100%)
- 99%
Persistence (0 day gap between refills)
- Patients with 0 day gap between prescription refills
- 78%
Original publication
Tafamidis Medication Adherence and Persistence in Patients with Transthyretin Amyloid Cardiomyopathy in Japan. ESC Heart Fail. Published 23 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →